Cassava Sciences, Inc. (SAVA) Financial Ratios
26 years of historical data (1999–2024) · Healthcare · Biotechnology
EV/EBITDA
N/A
—
5yr avg: N/A
P/FCF
N/A
—
5yr avg: N/A
30Y Low0.4·High45.1
P/B Ratio
↑
0.42
↓-43% vs avg
5yr avg: 0.75
30Y Low0.1·High1.3
ROE
↓
-17.2%
↓+35% vs avg
5yr avg: -26.4%
30Y Low-84%·High103%
Debt/EBITDA
N/A
—
5yr avg: N/A
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
SAVA Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Cassava Sciences, Inc. currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $64M | $110M | $135M | $170M | $246M | $25M | $13M | $1M | $4M | $4M | $11M |
| Enterprise Value | $-64807577 | $-18588560 | $14M | $-31223560 | $13M | $-67778899 | $-10055625 | $-18510205 | $-6743758 | $-14997767 | $-19860013 |
| P/E Ratio → | -2.54 | — | — | — | — | — | — | — | — | — | — |
| P/S Ratio | — | — | — | — | — | — | — | — | — | — | — |
| P/B Ratio | 0.42 | 0.75 | 0.98 | 0.75 | 0.97 | 0.28 | 0.59 | 0.07 | 0.39 | 0.20 | 0.39 |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
SAVA EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | — | — | — | — | — | — | — | — | — | — |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — | — | — |
SAVA Profitability
Margins and return-on-capital ratios measuring operating efficiency
A negative ROE of -17.2% indicates the company is currently destroying shareholder equity.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | — | — | — | — | — | — | — |
| Operating Margin | — | — | — | — | — | — | — | — | — | — | — |
| Net Profit Margin | — | — | — | — | — | — | — | — | — | — | — |
Return on Capital
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -17.2% | -17.2% | -53.3% | -31.7% | -18.7% | -11.1% | -22.2% | -44.7% | -84.1% | -61.9% | -40.8% |
| ROA | -15.7% | -15.7% | -50.3% | -30.4% | -17.9% | -10.8% | -21.2% | -42.3% | -79.1% | -58.0% | -38.8% |
| ROIC | -634.1% | -634.1% | -369.7% | -253.4% | -250.3% | — | — | — | — | — | — |
| ROCE | -99.9% | -99.9% | -58.0% | -33.2% | -19.0% | -11.3% | -23.8% | -45.4% | -84.3% | -62.3% | -40.9% |
SAVA Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
The company holds a net cash position — cash of $129M exceeds total debt of $0, providing substantial financial flexibility for buybacks, acquisitions, or weathering downturns.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — | — |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -0.88 | -0.88 | -0.88 | -0.92 | -1.01 | -1.04 | -1.01 | -1.08 | -1.00 | -1.07 |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — | — | — | — |
| Interest Coverage | — | — | — | — | — | — | — | — | — | — | — |
Net cash position: cash ($129M) exceeds total debt ($0)
SAVA Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
Cassava Sciences, Inc.'s current ratio of 11.62x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities. The current ratio has declined from 29.91x to 11.62x over the past 3 years.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 11.62 | 11.62 | 9.13 | 29.91 | 19.51 | 50.40 | 16.83 | 39.22 | 9.42 | 28.68 | 12.42 |
| Quick Ratio | 11.62 | 11.62 | 9.13 | 29.91 | 19.51 | 50.40 | 16.83 | 39.22 | 9.42 | 28.68 | 12.42 |
| Cash Ratio | 10.94 | 10.94 | 8.53 | 28.46 | 18.62 | 50.14 | 16.64 | 38.76 | 9.26 | 28.14 | 12.27 |
| Asset Turnover | — | — | — | — | — | — | — | — | — | — | — |
| Inventory Turnover | — | — | — | — | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | — | — | — | — | — | — | — | — | — | — |
SAVA Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Cassava Sciences, Inc. does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.5% | 0.0% | 0.0% | 0.0% | 0.0% |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.5% | 0.0% | 0.0% | 0.0% | 0.0% |
| Shares Outstanding | — | $47M | $42M | $40M | $39M | $26M | $17M | $11M | $7M | $7M | $7M |
Peer Comparison
Compare SAVA with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 SAVAYou | $64M | -2.5 | — | — | — | — | -17.2% | -634.1% | — |
 ACAD | $4B | 9.4 | 25.7 | 35.2 | 91.7% | 9.8% | 39.9% | 10.0% | 0.4 |
 PRAX | $8B | -20.9 | — | — | — | — | -45.8% | -65.0% | — |
 ATNM | $32M | -0.9 | — | — | 100.0% | -40274.4% | -167.0% | — | — |
 AVXL | $253M | -5.1 | — | — | — | — | -43.1% | — | — |
 ACIU | $244M | -2.8 | — | — | 100.0% | -1927.3% | -89.6% | -99.2% | — |
 BIIB | $29B | 22.3 | 11.7 | 14.2 | 70.5% | 19.1% | 7.4% | 6.5% | 2.5 |
 LLY | $1.0T | 47.8 | 34.3 | 115.6 | 83.8% | 45.6% | 101.2% | 41.8% | 1.4 |
 IONS | $12B | -31.1 | — | — | 98.3% | -40.5% | -70.7% | -12.8% | — |
 ALNY | $37B | 119.4 | 65.9 | 79.7 | 81.8% | 13.5% | 73.3% | 33.4% | 2.3 |
 IQV | $28B | 21.4 | 12.4 | 13.9 | 26.3% | 14.0% | 21.4% | 8.7% | 4.7 |
| Healthcare Median | — | 22.1 | 14.2 | 18.5 | 63.9% | -4.3% | -32.6% | -11.6% | 3.2 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 26 years · Updated daily
Consensus-Based Analysis Tools
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Check Valuation
Historical Returns
10-year return with dividends reinvested.
Calculate
DCA Calculator
See how regular investing compounds over time.
Run Numbers
Peer Comparison
Compare growth, multiples, and margins vs sector.
Compare
SAVA — Frequently Asked Questions
Quick answers to the most common questions about buying SAVA stock.
What is Cassava Sciences, Inc.'s P/E ratio?
Cassava Sciences, Inc.'s current P/E ratio is -2.5x. The historical average is 4.0x.
What is Cassava Sciences, Inc.'s ROE?
Cassava Sciences, Inc.'s return on equity (ROE) is -17.2%. The historical average is -21.5%.
Is SAVA stock overvalued?
Based on historical data, Cassava Sciences, Inc. is trading at a P/E of -2.5x. Compare with industry peers and growth rates for a complete picture.